

**Supplementary Table 1.** Characteristics of patients infected with the wild-type variant treated with monoclonal antibodies.

	N=49 (%)
Age, median (IQRs), ys	66 (52.5-76)
Male sex	31 (63.3)
Comorbidities	
COPD	7 (14.3)
Diabetes mellitus	6 (12.2)
Cardiovascular disease	18 (36.7)
Chronic renal failure	2 (4.1)
Solid cancer	4 (8.2)
Hematological malignancy	2 (4.1)
Solid organ/ Bone marrow transplantation	0
Obesity	10 (20.4)
Autoimmune disease	2 (4.1)
Charlson Comorbidity Index, median (IQRs)	2 (2-3)
Days from onset of symptoms to monoclonal antibodies infusion, median (IQRs)	3 (3-4.5)
Previous anti-SARS-CoV-2 vaccination	10 (20.4)
mRNA-1273 (Moderna)	4 (8.2)
BNT162b2 (Pfizer)	3 (6.1)
ChAdOx1 nCoV-19 (Astrazeneca)	3 (6.1)
Hospitalization	5 (10.2)
ICU admission	0
30-day mortality	2 (4.1)
Time to virological cure, days, median (IQRs)*	11 (8.5-19.5)

\* Time from monoclonal antibodies infusion and virological cure was calculated after excluding patients who died

COPD chronic obstructive pulmonary disease, ICU intensive care unit, IQRs interquartile ranges

**Supplementary Table 2.** Comparison of patients who met primary endpoint and those who did not.

	<b>Patients who met primary endpoint N=21 (%)</b>	<b>Patients who did not met primary endpoint N=144 (%)</b>	
Age, median (IQRs)	72 (56-79.5)	67 (57-75)	0.375
Male sex	14 (66.7)	67 (46.5)	0.085
Comorbidities			
COPD	2 (9.5)	23 (16)	0.744
Diabetes mellitus	3 (14.3)	19 (13.2)	1.0
Cardiovascular disease	13 (61.9)	81 (56.2)	0.625
Chronic renal failure	0	6 (4.2)	1.0
Solid cancer	0	11 (7.6)	0.362
Hematological malignancy	3 (14.3)	6 (4.2)	0.090
Solid organ/ Bone marrow transplantation	1 (4.8)	3 (2.1)	0.423
Obesity	0	19 (13.2)	0.135
Autoimmune disease	2 (9.5)	15 (10.4)	1.0
Charlson Comorbidity Index, median (IQRs)	2 (1-4)	2 (1-3)	0.221
Days from onset of symptoms to monoclonal antibodies infusion, median (IQRs)	5 (4-7)	4 (3-6)	0.068
Previous anti-SARS-CoV-2 vaccination			
mRNA-1273	6 (28.6)	38 (26.4)	0.833
BNT162b2	2 (9.5)	12 (8.3)	0.694
ChAdOx1 nCoV-19	3 (14.3)	20 (13.9)	1.0
Alpha (B.1.1.7) variant	1 (4.8)	6 (4.2)	1.0
Gamma (P.1) variant	6 (28.6)	116 (80.6)	<0.001
Gamma (P.1) variant	15 (71.4)	28 (19.4)	<0.001
Type of monoclonal antibodies combination			
Bamlanivimab/etesevimab	14 (66.7)	59 (41)	
Casirivimab/imdevimab	7 (33.3)	85 (59)	